Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Anyone can develop psoriatic arthritis, but it’s most common in people who already have psoriasis, affecting about 30 percent of people with the skin condition. Whether you’re managing just psoriatic ...

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial.

On Jan. 1, 2026, the price of my medication finally came down — and it will change my life. I have been living with psoriatic arthritis for over 40 years, a condition that I treat with a medication ...

When the immune system mistakenly attacks healthy cells in both the skin and joints, the result is psoriatic arthritis—a challenging condition that affects approximately 1 million Americans. While ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

People living with treatment-resistant active psoriatic arthritis reported meaningful improvements in pain, physical function and fatigue on TREMFYA through six months Additional pooled data from ...

At week 16, both trials showed a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response compared with placebo. Topline data were announced from two phase 3 trials ...

The Global Healthy Living Foundation (GHLF) is excited to present innovative and transformative research at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. This marks ...